Stocktoria
Phathom Pharmaceuticals, Inc. PHAT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-10-25
Phathom Pharmaceuticals, Inc. statistics & valuation
Market cap$855.0M
P / S4.9×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 87.1% | 85.6% | 75.5% | — | — |
| Operating margin | -91.4% | -502.2% | -24532.6% | — | — |
| Net margin | -126.3% | -605.1% | -29558.9% | — | — |
| FCF margin | -95.4% | -483.1% | -20412.6% | — | — |
| Return on assets | -85.4% | -88.4% | -48.7% | -120.0% | -76.0% |
| Return on equity | 50.5% | 131.8% | 277.1% | 264.3% | -199.4% |
| Debt / equity | -0.48× | -0.79× | -1.89× | -1.27× | 1.24× |
| Current ratio | 1.73 | 4.20 | 10.25 | 6.12 | 9.86 |
| Revenue growth | 216.9% | 8001.5% | — | — | — |
Source: SEC EDGAR filings · CIK 0001783183 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.